Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Update: Moderna’s Vaccine Shows Signs Of Lasting Protection

Plus: Pfizer CEO Relaxed About Vaccine Logistics

Executive Summary

The US is to ship only half of doses for Pfizer, Moderna COVID-19 vaccines in the first instance, while Rhizen Pharmaceuticals starts a Phase I trial of a DHODH inhibitor.

You may also be interested in...



Coronavirus Update: Moderna Snags Vaccine EUA

The FDA granted emergency authorization for Moderna's mRNA-1273 following a 17 December advisory committee vote in its favor. There have also been more supply deals and approvals in Asia.

UK Grants First Worldwide Authorization For Pfizer/BioNTech COVID-19 Vaccine

The UK's MHRA has granted an emergency authorization to the mRNA-based vaccine just nine days after receiving the final Phase III results from Pfizer.

Moderna Gets To Watch And Learn From Pfizer’s COVID-19 Vaccine Advisory Committee

US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC143423

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel